|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 12:24
|
IQVIA to acquire Charles River drug discovery assets (PBR)
|
|
|
The acquisition includes five sites specialising in various in vitro drug discovery services such as New Approach Methodologies (NAMs) and a small molecule AI platform. These assets are
The post IQVIA to acquire Charles River drug discovery assets appeared first on Pharmaceutical Business review....
|
|
|
25.02.26 - 13:06
|
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories.
These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Methodologies (NAMs) and a small molecule AI platform, designed to accelerate discovery programs and support growing demand for non animal research methods. Collectively, these assets are underpinned by more than 20 years of curated scientific and operational data, as well as extensive therapeutic expertise. Since their inception, these assets have enabled over 100 molecules to enter clinical trials and include several commercially approved drugs.
The acquisition complements IQVIA Laboratories' existing drug discove...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.02.26 - 14:12
|
IQVIA Q4 Earnings Up; Guides FY26 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - IQVIA Holdings Inc. (IQV), a healthcare data and analytics company, on Thursday reported higher net income and revenue in the fourth quarter compared with the previous year ......
|
|
|
|
|
|
|
|
|
05.02.26 - 13:03
|
IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance (Business Wire)
|
|
|
Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year
GAAP Net Income of $514 million for the fourth quarter, $1,360 million for the full year
Adjusted EBITDA of $1,046 million for the fourth quarter, $3,788 million for the full year
GAAP Diluted Earnings per Share of $2.99 for the fourth quarter, $7.84 for the full year
Adjusted Diluted Earnings per Share of $3.42 for the fourth quarter, $11.92 for the full year
R&D Solutions quarterly bookings of over $2.7 billion, representing a book-to-bill ratio of 1.18x
R&D Solutions contracted backlog of $32.7 billion, up 5.3% year-over-year
R&D Solutions Revenue of $2,333 million for the fourth quarter, up 9.9% year-over-year, $8,896 million for the full year, up 4.3% year-over-year
TAS Revenue of $1,821 million for the fourth quarter, up 9.8% year-over-year, $6,626 million for the full year, up 7.6% year-over-year
Operating Cash Flow of $735 million, bringing full-year Operating Cash Flow to $2,654 million
Free Cash Flow of $561 mill...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
